Currently Recruiting Clinical Trials

Currently Recruiting Clinical Trials are listed below. If you have any questions about our current research, please contact our research department at research@hurongastro.com or call 734-714-0523.

Currently Recruiting Clinical Trials

 

  • Phase III, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Multicenter Study to Evaluate the Efficacy (Induction Of Remission) and Safety of Etrolizumab Compared with Adalimumab and Placebo in Patients with Moderate to Severe Ulcerative Colitis who are Naive to TNF Inhibitors - GA28948 (Hibiscus)

  • A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis – AMBG (Lucent 2)

  • A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis – AMAN (Lucent 1)

  • A phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Naïve Subjects with Moderately-to-Severely Active Crohn’s Disease (Seavue)

  • A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis IND#127846 (Reverse)

  • A Phase 2b/3, Multicentered, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis (AbbVie M14-234)
     
  • A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in subjects with Ulcerative Colitis (AbbVie M14-533)
     
  • An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy with Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects with Crohn's Disease Stratified at Higher Risk for Developing Complications (Takeda EXPLORER) 
     
  • A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcohlic Steatohepatitis (REGENERATE) 
                         
  • A Phase 4 Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (AbbVie LEGACY)